Mast E E, Kuramoto I K, Favorov M O, Schoening V R, Burkholder B T, Shapiro C N, Holland P V
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Infect Dis. 1997 Jul;176(1):34-40. doi: 10.1086/514037.
To evaluate antibody to hepatitis E virus (anti-HEV) seroreactivity, 5000 US blood donors were tested for anti-HEV by two EIAs: a mosaic protein assay (MPr-EIA) and a recombinant protein assay (RPr-EIA). Overall, 59 (1.2%) were seroreactive by MPr-EIA and 70 (1.4%) were seroreactive by RPr-EIA. The overall concordance between tests was 98.5% (4925/5000); the concordance among reactive sera by either test was only 27% (27/102). In a case-control study, seroreactive persons were more likely than seronegative persons to have traveled to countries in which HEV is endemic (odds ratio [OR] for MPr-EIA = 4.3, P < .001; OR for RPr-EIA = 2.5, P = .005), but 31% of MPr-EIA anti-HEV-reactive persons and 38% of RPr-EIA anti-HEV-reactive persons had no history of international travel. These findings suggest that travelers to regions in which HEV is endemic can acquire subclinical HEV infection. The significance of anti-HEV seroreactivity among persons without an international travel history needs to be determined.
为评估戊型肝炎病毒抗体（抗-HEV）的血清反应性，采用两种酶免疫测定法（EIA）对5000名美国献血者进行了抗-HEV检测：一种是镶嵌蛋白测定法（MPr-EIA），另一种是重组蛋白测定法（RPr-EIA）。总体而言，MPr-EIA检测显示59人（1.2%）血清反应阳性，RPr-EIA检测显示70人（1.4%）血清反应阳性。两种检测方法之间的总体一致性为98.5%（4925/5000）；两种检测方法中任何一种检测呈反应性的血清之间的一致性仅为27%（27/102）。在一项病例对照研究中，血清反应阳性者比血清反应阴性者更有可能前往戊型肝炎流行的国家（MPr-EIA的优势比[OR]=4.3，P<.001；RPr-EIA的OR=2.5，P=.005），但31%的MPr-EIA抗-HEV反应阳性者和38%的RPr-EIA抗-HEV反应阳性者没有国际旅行史。这些发现表明，前往戊型肝炎流行地区的旅行者可能会感染亚临床戊型肝炎病毒。无国际旅行史者抗-HEV血清反应阳性的意义有待确定。
